Emerging evidence and treatment paradigm of non-small cell lung cancer

Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also dramatically improved in an unprecedented speed. The personalized treatment paradigm evolved every year. In this review, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Si-Yang Maggie, Zheng, Mei-Mei, Pan, Yi, Liu, Si-Yang, Li, Yangqiu, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108547/
https://www.ncbi.nlm.nih.gov/pubmed/37069698
http://dx.doi.org/10.1186/s13045-023-01436-2
_version_ 1785026870882861056
author Liu, Si-Yang Maggie
Zheng, Mei-Mei
Pan, Yi
Liu, Si-Yang
Li, Yangqiu
Wu, Yi-Long
author_facet Liu, Si-Yang Maggie
Zheng, Mei-Mei
Pan, Yi
Liu, Si-Yang
Li, Yangqiu
Wu, Yi-Long
author_sort Liu, Si-Yang Maggie
collection PubMed
description Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also dramatically improved in an unprecedented speed. The personalized treatment paradigm evolved every year. In this review, we summarize the promising agents that have shifted the treatment paradigm for NSCLC patients across all stages, including targeted therapy and immunotherapy using checkpoint inhibitors. Based on recent evidence, we propose treatment algorithms for NSCLC and propose several unsolved clinical issues, which are being explored in ongoing clinical trials. The results of these trials are likely to impact future clinical practice.
format Online
Article
Text
id pubmed-10108547
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101085472023-04-18 Emerging evidence and treatment paradigm of non-small cell lung cancer Liu, Si-Yang Maggie Zheng, Mei-Mei Pan, Yi Liu, Si-Yang Li, Yangqiu Wu, Yi-Long J Hematol Oncol Review Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also dramatically improved in an unprecedented speed. The personalized treatment paradigm evolved every year. In this review, we summarize the promising agents that have shifted the treatment paradigm for NSCLC patients across all stages, including targeted therapy and immunotherapy using checkpoint inhibitors. Based on recent evidence, we propose treatment algorithms for NSCLC and propose several unsolved clinical issues, which are being explored in ongoing clinical trials. The results of these trials are likely to impact future clinical practice. BioMed Central 2023-04-17 /pmc/articles/PMC10108547/ /pubmed/37069698 http://dx.doi.org/10.1186/s13045-023-01436-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Liu, Si-Yang Maggie
Zheng, Mei-Mei
Pan, Yi
Liu, Si-Yang
Li, Yangqiu
Wu, Yi-Long
Emerging evidence and treatment paradigm of non-small cell lung cancer
title Emerging evidence and treatment paradigm of non-small cell lung cancer
title_full Emerging evidence and treatment paradigm of non-small cell lung cancer
title_fullStr Emerging evidence and treatment paradigm of non-small cell lung cancer
title_full_unstemmed Emerging evidence and treatment paradigm of non-small cell lung cancer
title_short Emerging evidence and treatment paradigm of non-small cell lung cancer
title_sort emerging evidence and treatment paradigm of non-small cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108547/
https://www.ncbi.nlm.nih.gov/pubmed/37069698
http://dx.doi.org/10.1186/s13045-023-01436-2
work_keys_str_mv AT liusiyangmaggie emergingevidenceandtreatmentparadigmofnonsmallcelllungcancer
AT zhengmeimei emergingevidenceandtreatmentparadigmofnonsmallcelllungcancer
AT panyi emergingevidenceandtreatmentparadigmofnonsmallcelllungcancer
AT liusiyang emergingevidenceandtreatmentparadigmofnonsmallcelllungcancer
AT liyangqiu emergingevidenceandtreatmentparadigmofnonsmallcelllungcancer
AT wuyilong emergingevidenceandtreatmentparadigmofnonsmallcelllungcancer

Ejemplares similares